Objective: Despite the widespread use of propofol for painless abortion, it is frequently associated with cardiopulmonary adverse events. Ciprofol, a novel intravenous anesthetic agent, demonstrates a more favorable respiratory and hemodynamic stability profile. The aims of this study were to evaluate the efficacy and safety of ciprofol-nalbuphine combination in mitigating cardiopulmonary complications and enhancing recovery following painless abortion procedures. Methods: A total of 120 patients scheduled for elective painless abortion, aged 18-39 years, ASA physical status I or II, were selected. They were randomly divided into a Propofol-Nalbuphine group (PN group, n = 60) and a Ciprofol-Nalbuphine group (CN group, n = 60) using a random number table. Anesthesia was induced by intravenous injection of nalbuphine 0.1 mg/kg, followed 3 minutes later by intravenous injection of propofol (2 mg/kg, PN group) or ciprofol (0.4 mg/kg, CN group). Anesthesia was maintained by continuous intravenous infusion of propofol or ciprofol. The incidence of cardiopulmonary adverse reactions (respiratory depression, hypotension, bradycardia), changes in heart rate (HR), mean arterial pressure (MAP), and pulse oxygen saturation (SpOsub2/sub) at different time points were observed. Additionally, drug dosage, induction time, operative time, recovery time, injection pain, postoperative uterine contraction pain, and surgeon satisfaction were compared between the two groups. Results: Compared with PN, CN demonstrated a lower incidence of cardiopulmonary adverse reactions (15% vs. 40%,i P/i 0.05) and shorter recovery time (2.8 ± 1.8 vs. 1.9 ± 0.8 min, iP/i 0.05). The CN group also had reduced injection pain (3.3% vs. 16.6%) and intraoperative body movement (10% vs. 20%) (both iP/i 0.05). Surgeons reported higher satisfaction scores with CN (8.9 ± 1.0 vs. 8.0 ± 1.0, iP/i 0.001). MAP decreased after induction in both groups, with no intergroup difference (iP/i 0.05). Anesthesia induction time, operative time, and postoperative uterine contraction pain did not differ significantly between groups (iP/i 0.05). Conclusion: Intravenous anesthesia using ciprofol 0.4 mg/kg combined with nalbuphine 0.1 mg/kg is safe and effective for painless abortion. It offers advantages such as fewer cardiopulmonary adverse events, faster recovery, and less injection pain, making it worthy of clinical application and promotion.
Huang et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: